table td { font-size: 16px !important; }
Category

NASH

Graviton
0
NASH
01/2023

Denifanstat (DEN), a first-in-class fatty acid synthase (FASN) inhibitor, significantly reduces plasma tripalmitin, a marker of de novo lipogenesis, in NASH patients in the FASCINATE-1 and FASCINATE-2 clinical studies

NASH-TAG
Read More
Graviton
0
NASH
01/2023

Serum metabolomic, lipidomic and proteomic profiling identifies new biomarkers associated with the treatment of denifanstat, a fatty acid synthase inhibitor, in NASH patients

NASH-TAG
Read More
Graviton
0
NASH
11/2022

Correlation between AI-based digital pathology and non-invasive tests (NITs) – baseline data from the FASCINATE-2 phase 2b clinical study of denifanstat in patients with F2/F3 NASH

AASLD The Liver Meeting
Read More
Graviton
0
NASH
11/2022

A baseline metabolomic signature predicts liver fat (MRI-PDFF) response for denifanstat, a first-in-class, fatty acid synthase (FASN) inhibitor: analysis in FASCINATE-1 and FASCINATE-2 clinical studies

AASLD The Liver Meeting
Read More
Graviton
0
NASH
11/2022

Serum proteomic profiling reveals that the fatty acid synthase (FASN) inhibitor denifanstat provides metabolic benefits via increasing fibroblast growth factor 19 (FGF19) and decreasing 3-hydroxy-3-methylglutaryl-coa synthase 1 (HMGCS1) in NASH patients

AASLD The Liver Meeting
Read More
Graviton
12
NASH
09/2022

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

Scientific Reports
Read More
Graviton
12
NASH
06/2022

A baseline signature of metabolites involving the gut-liver axis predicts MRI-PDFF response to FASN inhibitor TVB-2640 in NASH patients: results from the FASCINATE-1 study

EASL International Liver Congress
Read More
Graviton
12
NASHPUBLICATIONS
05/2022

Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640: efficacy, safety and biomarker results from a global phase 2 randomized pbo-controlled NASH trial, FASCINATE-1

Digestive Disease Week
Read More
Graviton
9
NASH
01/2022

Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640 demonstrates robust clinical efficacy and safety in a global phase 2 randomized placebo-controlled NASH trial (FASCINATE-1)

NASH-TAG
Read More
Graviton
9
NASH
11/2021

TVB-2640, a novel, first-in-class, fatty acid synthase (FASN) inhibitor: biomarker and metabolomic correlations with clinical MRI-PDFF response

NASH Summit
Read More